This is a Validated Antibody Database (VAD) review about human CD3G, based on 137 published articles (read how Labome selects the articles), using CD3G antibody in all methods. It is aimed to help Labome visitors find the most suited CD3G antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
CD3G synonym: CD3-GAMMA; IMD17; T3G

Invitrogen
mouse monoclonal (SK7)
  • flow cytometry; human; loading ...; fig s1a
Invitrogen CD3G antibody (eBioscience, 17-0036-42) was used in flow cytometry on human samples (fig s1a). BMC Cancer (2019) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; loading ...; fig 3f, 3g
Invitrogen CD3G antibody (Invitrogen, SK7) was used in flow cytometry on human samples (fig 3f, 3g). Brain Pathol (2020) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 2 ug/ml; loading ...; fig 4a
Invitrogen CD3G antibody (eBioscience, 16-0037-85) was used in blocking or activating experiments on human samples at 2 ug/ml (fig 4a). Diagn Pathol (2019) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; rhesus macaque; 1:200; loading ...; fig 3g
Invitrogen CD3G antibody (Invitrogen, 47-0037-41) was used in flow cytometry on rhesus macaque samples at 1:200 (fig 3g). Nature (2019) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; 1:200; loading ...; fig 2s1b
Invitrogen CD3G antibody (eBioscience, 45-0037-71) was used in flow cytometry on human samples at 1:200 (fig 2s1b). elife (2019) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; loading ...; fig 1a
Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples (fig 1a). Arthritis Res Ther (2019) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; loading ...; fig 1a
Invitrogen CD3G antibody (eBioscience, 45-0036) was used in flow cytometry on human samples (fig 1a). Cell (2019) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...; fig s2a
Invitrogen CD3G antibody (Life Technologies, UCHT1) was used in flow cytometry on human samples (fig s2a). Nat Med (2019) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; loading ...; fig s18b
Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples (fig s18b). Science (2018) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; loading ...; fig s3i
Invitrogen CD3G antibody (eBiosciences, 13-0037-82) was used in flow cytometry on human samples (fig s3i). Cell (2018) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...; fig s4a
Invitrogen CD3G antibody (eBiosciences, UCHT1) was used in flow cytometry on human samples (fig s4a). Sci Immunol (2018) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; loading ...; fig 1b
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig 1b). J Clin Invest (2018) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig 2c
In order to study the involvement of RANKL in decidual M2 macrophage polarization, Invitrogen CD3G antibody (ebioscience, 16-0037) was used in flow cytometry on human samples (fig 2c). Cell Death Dis (2017) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; human; loading ...; fig s1
Invitrogen CD3G antibody (Invitrogen, S4.1) was used in flow cytometry on human samples (fig s1). Eur J Immunol (2018) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; loading ...; tbl s1
In order to investigate the effect of Shigella infection on human lymphocytes, Invitrogen CD3G antibody (eBioscience, 11-0037-42) was used in flow cytometry on human samples (tbl s1). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...; tbl s1
In order to investigate the effect of Shigella infection on human lymphocytes, Invitrogen CD3G antibody (eBioscience, 13-0038-82) was used in flow cytometry on human samples (tbl s1). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 1 ug/ml; loading ...; fig 6d
Invitrogen CD3G antibody (ebioscience, OKT3) was used in blocking or activating experiments on human samples at 1 ug/ml (fig 6d). PLoS ONE (2017) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; 1:200; loading ...; fig 4a
In order to study the interaction between CD100 and CD72 and its role in T cell proliferation, Invitrogen CD3G antibody (eBiosciences, UCHT1) was used in flow cytometry on human samples at 1:200 (fig 4a). Front Immunol (2017) ncbi
mouse monoclonal (S4.1 (7D6))
  • flow cytometry; human; loading ...; fig 1e
Invitrogen CD3G antibody (Invitrogen, MHCD0331) was used in flow cytometry on human samples (fig 1e). J Clin Invest (2017) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; loading ...; tbl 1
In order to investigate infiltrating T cells in liver cancer through single-cell sequencing, Invitrogen CD3G antibody (eBioscience, 16-0037-85) was used in blocking or activating experiments on human samples (tbl 1). Cell (2017) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; fig 3a
In order to generate T cells from cord blood hematopoietic progenitor cells transduced to express an antigen receptor as assess their ability to limit malignant cells and graft versus host disease, Invitrogen CD3G antibody (eBioscience, 48-0038-42) was used in flow cytometry on human samples (fig 3a). Oncoimmunology (2017) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 30 ng/ml; loading ...; fig s9
In order to find neoantigens in human mantle-cell lymphomas using samples from human patients, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples at 30 ng/ml (fig s9). Nature (2017) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...; fig 3e
In order to investigate origin of tumor-infiltrating T regulatory cells in breast cancer samples, Invitrogen CD3G antibody (Thermo Fisher Scientific, 48-0038) was used in flow cytometry on human samples (fig 3e). Cell Res (2017) ncbi
mouse monoclonal (HIT3a)
  • flow cytometry; human; loading ...; fig 3a
In order to investigate origin of tumor-infiltrating T regulatory cells in breast cancer samples, Invitrogen CD3G antibody (Thermo Fisher Scientific, 11-0039) was used in flow cytometry on human samples (fig 3a). Cell Res (2017) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...; fig 4b
In order to study the differentiation of innate lymphoid cells, Invitrogen CD3G antibody (eBioscience, 11-0038) was used in flow cytometry on human samples (fig 4b). Cell (2017) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; loading ...; fig 3a
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig 3a). J Immunol (2017) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; loading ...; fig 2a
Invitrogen CD3G antibody (eBioscience, OKT-3) was used in flow cytometry on human samples (fig 2a). Oncoimmunology (2017) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; loading ...; fig 1a
In order to characterize the periferal blood lymphocytes phenotype in tacrolimus-treated liver transplanted patients., Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples (fig 1a). Med Princ Pract (2017) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; loading ...; fig 1
In order to study the restoration of immune function in chronic HIV infection, Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig 1). J Clin Invest (2017) ncbi
mouse monoclonal (HIT3a)
  • flow cytometry; human; loading ...
In order to characterize gammadelta T cell subsets from healthy humans, Invitrogen CD3G antibody (ebioscience, HIT3a) was used in flow cytometry on human samples . Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (OKT3)
  • immunocytochemistry; human; tbl 1
In order to discuss methods to visualize gangliosides involved in CD4 positive T cell activation, Invitrogen CD3G antibody (eBioscience, 16-0037-81) was used in immunocytochemistry on human samples (tbl 1). J Vis Exp (2016) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; loading ...; fig 2c
Invitrogen CD3G antibody (eBiosciences, OKT3) was used in flow cytometry on human samples (fig 2c). PLoS Pathog (2016) ncbi
mouse monoclonal (UCHT1, HIB19)
In order to identify a role for CK2 in healthy human thymocytes in the selection of the gamma delta T-cell lineage, Invitrogen CD3G antibody (eBioscience, UCHT1) was used . Leukemia (2017) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; loading ...; fig 1b
In order to investigate the role of Eomes in the retention of liver natural killer cells, Invitrogen CD3G antibody (eBiosciences, SK7) was used in flow cytometry on human samples (fig 1b). J Immunol (2016) ncbi
mouse monoclonal (UCHT1, HIB19)
In order to investigate how differences in B cell populations may contribute to HIV susceptibility, Invitrogen CD3G antibody (Invitrogen, UCHT1) was used . AIDS Res Hum Retroviruses (2016) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 2.5 ug/ml; loading ...; fig 7d
In order to find that internal membrane reservoirs in T lymphocytes are recruited, likely through exocytosis, to induce large active deformations, Invitrogen CD3G antibody (eBioscience, 16-0037-85) was used in blocking or activating experiments on human samples at 2.5 ug/ml (fig 7d). Mol Biol Cell (2016) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; fig 6a
In order to develop a method to quantify both the spatial distribution of a protein and its colocalization status, Invitrogen CD3G antibody (eBiosciences, 16-0037) was used in blocking or activating experiments on human samples (fig 6a). Mol Biol Cell (2016) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; fig 1
Invitrogen CD3G antibody (eBioscience, 16-0037) was used in blocking or activating experiments on human samples (fig 1). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (S4.1 (7D6))
  • flow cytometry; human; loading ...
In order to elucidate the mechanisms by which DRibbles induce T-cell activation, Invitrogen CD3G antibody (Invitrogen, MHCD0331) was used in flow cytometry on human samples . Cell Death Dis (2016) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples . elife (2016) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; fig 1a
In order to assess the effects of platelet-derived ectosomes on natural killer cells, Invitrogen CD3G antibody (eBiosciences, SK7) was used in flow cytometry on human samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (UCHT1)
  • blocking or activating experiments; human; 1 ug/ml; loading ...; fig s3a
In order to use knockout mice to determine the role of cereblon in T cells, Invitrogen CD3G antibody (eBiosciences, UCHT1) was used in blocking or activating experiments on human samples at 1 ug/ml (fig s3a). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (UCHT1, HIB19)
In order to characterize B cells and antibody repertoires from injection drug users, Invitrogen CD3G antibody (Invitrogen, UCHT1) was used . PLoS ONE (2016) ncbi
mouse monoclonal (UCHT1)
  • immunohistochemistry; human; 1:200; loading ...; fig 5d
In order to develop methods to study aberrant crypt foci, Invitrogen CD3G antibody (eBioscience, UCHT1) was used in immunohistochemistry on human samples at 1:200 (fig 5d). Mol Cancer Res (2016) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; fig 1
Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples (fig 1). Oncotarget (2016) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; fig S1
In order to study chronic hepatitis C virus infections and the functional dichotomy of V-delta2 gamma-delta T cells and their role in cytotoxicity and not IFN-gamma production, Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples (fig S1). Sci Rep (2016) ncbi
mouse monoclonal (UCHT1)
  • mass cytometry; human; loading ...; tbl 1, 2
In order to use elemental metal isotopes conjugated to monoclonal antibodies and study intracellular functional markers and surface phenotypic markers on natural killer cells, Invitrogen CD3G antibody (Life Technologies, UCHT1) was used in mass cytometry on human samples (tbl 1, 2). Methods Mol Biol (2016) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; loading ...; fig s2a
  • immunohistochemistry - paraffin section; human; fig 4b
In order to investigate if ectopic expression of CX3CR1 enhances the homing of adoptively transferred T cells towards CX3CL1-producing tumors, resulting in increased T cell infiltration in tumor tissues, Invitrogen CD3G antibody (eBioscience, EB16-0037-85) was used in blocking or activating experiments on human samples (fig s2a) and in immunohistochemistry - paraffin section on human samples (fig 4b). J Immunother Cancer (2016) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, 48-0038-42) was used in flow cytometry on human samples . Oncoimmunology (2016) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; fig 8
Invitrogen CD3G antibody (eBioscience, 16-0037-85) was used in blocking or activating experiments on human samples (fig 8). J Exp Med (2016) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig 4
Invitrogen CD3G antibody (eBioscience, OKT-3) was used in flow cytometry on human samples (fig 4). Sci Rep (2016) ncbi
mouse monoclonal (UCHT1, HIB19)
In order to characterize the gut-associated lymphoid tissue of HIV-controllers, Invitrogen CD3G antibody (eBioscience, UCHT1) was used . Immunol Res (2016) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; fig 2
In order to investigate the control of LAT recruitment to the immune synapse and T-cell activation in vivo by IFT20, Invitrogen CD3G antibody (eBioscence, 16-0037-85) was used in blocking or activating experiments on human samples (fig 2). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; fig 5
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples (fig 5). PLoS Pathog (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; loading ...
In order to demonstrate that TGF-beta induces the differentiation of human CXCL13-producing CD4 positive T cells from naive CD4 positive T cells, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples . Eur J Immunol (2016) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; fig 3
Invitrogen CD3G antibody (Tonbo, 25-0038) was used in flow cytometry on human samples (fig 3). Nat Commun (2015) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; fig 7
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples (fig 7). Eur J Immunol (2016) ncbi
mouse monoclonal (HIT3a)
  • ELISA; human; fig 2
In order to characterize a bispecific scFv antibody targeting of human melanoma made in transgenic cattle called r28M, Invitrogen CD3G antibody (eBioscience, 16?C0039) was used in ELISA on human samples (fig 2). PLoS ONE (2015) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; loading ...; fig s1a
In order to study age-related changes in human immunity during a primary virus infection experimentally induced by immunization with live-attenuated yellow fever vaccine, Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig s1a). J Immunol (2015) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; mouse; loading ...
In order to assess the effects of allosteric inhibitors on different mutant forms of isocitrate dehydrogenase 1 in leukemia, Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on mouse samples . Nat Chem Biol (2015) ncbi
mouse monoclonal (HIT3a)
  • flow cytometry; human; loading ...; fig e3d
In order to discuss the importance of IL-5 positive Th2 cells to allergies, Invitrogen CD3G antibody (eBioscience, (HIT3A) was used in flow cytometry on human samples (fig e3d). J Allergy Clin Immunol (2016) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...; fig e3d
In order to discuss the importance of IL-5 positive Th2 cells to allergies, Invitrogen CD3G antibody (Invitrogen, UCHT1) was used in flow cytometry on human samples (fig e3d). J Allergy Clin Immunol (2016) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; fig 1
Invitrogen CD3G antibody (eBioscience, 16-0037-85) was used in blocking or activating experiments on human samples (fig 1). MAbs (2016) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human
In order to determine the proportions, phenotype, survival, and apoptotic susceptibility of Tregs in sarcoidosis, Invitrogen CD3G antibody (eBiosciences, SK7) was used in flow cytometry on human samples . Respir Res (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 1 ug/ml; fig 6c
Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples at 1 ug/ml (fig 6c). Nat Immunol (2015) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig 1
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig 1). Cancer Immunol Immunother (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; fig s5
In order to study how conformational changes control T cell receptor association and activity of Zap70, Invitrogen CD3G antibody (eBiosciences, 16-0037) was used in blocking or activating experiments on human samples (fig s5). Nat Immunol (2015) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...; fig 2a
In order to examine the effects of immunosuppressive agents on Polyomavirus BKV-specific T cells, Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples (fig 2a). Kidney Int (2015) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; fig 4
In order to discuss the role of T cells in Rasmussen encephalitis, Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples (fig 4). J Neuroinflammation (2015) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig 1b
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig 1b). Proc Natl Acad Sci U S A (2015) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig s3
In order to determine the competitive advantage for human hematopoietic stem cells in vivo provided by CCND1-CDK4-mediated cell cycle progression, Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig s3). J Exp Med (2015) ncbi
mouse monoclonal (HIT3a)
  • flow cytometry; human; fig s3
In order to determine the competitive advantage for human hematopoietic stem cells in vivo provided by CCND1-CDK4-mediated cell cycle progression, Invitrogen CD3G antibody (eBioscience, HIT3A) was used in flow cytometry on human samples (fig s3). J Exp Med (2015) ncbi
mouse monoclonal (MEM-57)
  • immunohistochemistry; human; 1:200
In order to characterize placental gastrokine 2 expression in the placenta, Invitrogen CD3G antibody (Thermo Scientific, MA1-19454) was used in immunohistochemistry on human samples at 1:200. Histochem Cell Biol (2015) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, 48-0037-42) was used in flow cytometry on human samples . Blood Cancer J (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 10 ng/ml; fig 1
In order to discuss how to use induced-pluripotent stem cells to generate neuron-like cells, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples at 10 ng/ml (fig 1). J Chin Med Assoc (2015) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples . J Immunol (2015) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; human; fig 6
In order to report the phase I trial results of CDX-301, Invitrogen CD3G antibody (Invitrogen, S4.1) was used in flow cytometry on human samples (fig 6). Bone Marrow Transplant (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 5 ug/ml
In order to study dysregulation of CD62L expression during HIV infection, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples at 5 ug/ml. J Virol (2015) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
In order to study the role of melanoma cell surface-associated calreticulin in melphalan-induced antitumor immunity, Invitrogen CD3G antibody (eBioscience, 48-0038) was used in flow cytometry on human samples . Cancer Res (2015) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; tbl 1
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples (tbl 1). J Immunol (2015) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human; tbl 1
Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples (tbl 1). J Immunol (2015) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; human; tbl s1
In order to examine the early impact of viral replicative capacity on HIV-1 immunopathogenesis, Invitrogen CD3G antibody (Invitrogen, S4.1) was used in flow cytometry on human samples (tbl s1). Proc Natl Acad Sci U S A (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; fig 3
In order to describe the phenotype and functional potential of metastatic differentiated thyroid cancer-associated PD-1 positive T cells, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples (fig 3). Cancer Immunol Res (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; loading ...
In order to demonstrate a role for the actin network in regulating LFA-1 activity in T cells, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples . J Cell Biol (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 0.5 ug/ml
Invitrogen CD3G antibody (eBIoscience, OKT3) was used in blocking or activating experiments on human samples at 0.5 ug/ml. J Biol Chem (2015) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; mouse; 1:2000
In order to test if mesenchymal stromal cells support the growth and survival of leukemic stem cells in vitro, Invitrogen CD3G antibody (Invitrogen, S4.1PB) was used in flow cytometry on mouse samples at 1:2000. Stem Cell Res (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human
Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples . J Autoimmun (2015) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples . J Allergy Clin Immunol (2015) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; fig 6g
In order to test if flow cytometry can be used to find mantle cell lymphoma, Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples (fig 6g). Cytometry B Clin Cytom (2014) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human
Invitrogen CD3G antibody (e-Bioscience, SK7) was used in flow cytometry on human samples . Nat Commun (2014) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples . J Immunol (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; tbl 1
Invitrogen CD3G antibody (eBiosciences, UCHT1) was used in flow cytometry on human samples (tbl 1). J Gen Virol (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 2 ug/ml
Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples at 2 ug/ml. PLoS Negl Trop Dis (2014) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; 50 ng/ml
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples at 50 ng/ml. J Leukoc Biol (2014) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human
In order to study the role of CD93 molecule in mature dendritic cells and T cells, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples . Immunobiology (2015) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples . Clin Cancer Res (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples . Med Microbiol Immunol (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples . J Exp Med (2014) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
In order to study the cell mediated immune response to JCV T-Ag in patients with colorectal adenomatous polyps or cancers, Invitrogen CD3G antibody (eBioscience, 45-0037-42) was used in flow cytometry on human samples . Gut Microbes (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples . J Infect Dis (2014) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (eBiosciences, OKT3) was used in flow cytometry on human samples . J Clin Immunol (2014) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (e-Biosciences, OKT-3) was used in flow cytometry on human samples . J Clin Immunol (2014) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples . J Immunol Res (2014) ncbi
mouse monoclonal (S4.1 (7D6))
  • flow cytometry; human
In order to study virus-specific human memory T-cell activation in response to Dribble-mediated cross-presentation of viral antigens, Invitrogen CD3G antibody (Invitrogen, MHCD0331) was used in flow cytometry on human samples . J Transl Med (2014) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (UCHT1, HIB19)
In order to investigate the effects of lymphopenia and chronic exposure to IFN on T cell homeostasis, Invitrogen CD3G antibody (Invitrogen, UCHT1) was used . PLoS Pathog (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; tbl 1
In order to study the effect of innate lymphoid cells on B cells, Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples (tbl 1). Nat Immunol (2014) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, 14-0037-82) was used in flow cytometry on human samples . Clin Cancer Res (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples . PLoS Pathog (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...; fig 1
In order to discuss the importance of assessing immune competence in cancer patients, Invitrogen CD3G antibody (Invitrogen, UCHT1) was used in flow cytometry on human samples (fig 1). Cancer Immunol Immunother (2014) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 3 ug/ml
Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples at 3 ug/ml. J Immunol (2014) ncbi
mouse monoclonal (UCHT1)
  • blocking or activating experiments; human
In order to test the effect of different Mycobacterium tuberculosis molecules on HIV-1 replication, Invitrogen CD3G antibody (Ebioscience, UCHT1) was used in blocking or activating experiments on human samples . PLoS ONE (2013) ncbi
mouse monoclonal (HIT3a)
  • blocking or activating experiments; human; 0.5 ug/ml; fig 1
Invitrogen CD3G antibody (eBioscience, HIT3a) was used in blocking or activating experiments on human samples at 0.5 ug/ml (fig 1). Ann Rheum Dis (2015) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human
Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples . Clin Exp Immunol (2014) ncbi
mouse monoclonal (UCHT1, HIB19)
In order to correlate biomarkers associated with coagulation, monocyte activation, and inflammation in elite controllers of HIV infection, Invitrogen CD3G antibody (eBioscience, UCHT1) was used . J Infect Dis (2014) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; human
In order to use zinc-finger nucleases to simultaneous modify ccr5 and cxcr4 in primary human CD4(+) T cells and introduce these cells into a humanized mouse model of HIV-1 infection, Invitrogen CD3G antibody (Invitrogen, S4.1) was used in flow cytometry on human samples . Blood (2014) ncbi
mouse monoclonal (SK7)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, SK7) was used in flow cytometry on human samples . J Hepatol (2014) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, UCHT1) was used in flow cytometry on human samples . Ann Rheum Dis (2014) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; human
In order to study facilitation of HIV-1 transmission to cervico-vaginal tissue ex vivo by interleukin-7, Invitrogen CD3G antibody (Invitrogen, noca) was used in flow cytometry on human samples . PLoS Pathog (2013) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; human; fig 5
In order to analyze the proliferation and functional profile of circulating double positive T cells from acutely HIV-infected individuals and chronically HIV-infected viral controllers, Invitrogen CD3G antibody (Invitrogen, S4.1) was used in flow cytometry on human samples (fig 5). J Immunol (2012) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; loading ...
In order to characterize two pathogenic, noncoding aberrations of UNC13D in patients with familial hemophagocytic lymphohistiocytosis, Invitrogen CD3G antibody (eBiosciences, UHCT1) was used in flow cytometry on human samples . Blood (2011) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 2.5 ug/ml
Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples at 2.5 ug/ml. PLoS ONE (2011) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig S2
In order to examine tumor and nonadjacent normal breast tissue from women with breast cancer, who either had or had not received neoadjuvant chemotherapy before surgery, Invitrogen CD3G antibody (eBioscience, 45-0037-42) was used in flow cytometry on human samples (fig S2). Proc Natl Acad Sci U S A (2012) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig 2
In order to investigate IL-15-driven NK receptor induction in CD8+ T cells, Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig 2). Immunobiology (2011) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; mouse; fig 3
In order to compare the therapeutic efficacy of CD19-specific human primary T cells that constitutively express gamma(c)-cytokines, Invitrogen CD3G antibody (Caltag, S4.1) was used in flow cytometry on mouse samples (fig 3). Blood (2010) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; fig 1
In order to study T regulatory cells in inflamed human liver samples, Invitrogen CD3G antibody (eBioscience, UCHT-1) was used in flow cytometry on human samples (fig 1). J Immunol (2010) ncbi
mouse monoclonal (S4.1)
  • flow cytometry; human
In order to study the improvement of simultaneous phenotype-specific telomere length measurement by FISH-flow cytometry by quantum dots thermal stability, Invitrogen CD3G antibody (Invitrogen, noca) was used in flow cytometry on human samples . J Immunol Methods (2009) ncbi
mouse monoclonal (UCHT1)
  • flow cytometry; human; tbl 1
In order to characterize lymphocyte subgroups in peripheral blood of advanced stage lung cancer patients, Invitrogen CD3G antibody (eBioscience, 15-0038) was used in flow cytometry on human samples (tbl 1). Med Oncol (2010) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig 4
  • flow cytometry; rhesus macaque; fig 4
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples (fig 4) and in flow cytometry on rhesus macaque samples (fig 4). J Virol (2008) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human
In order to develop a system for the decoration of enveloped viruses with functionally active cytokines, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples . J Virol (2007) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human; 0.5 ug/ml
In order to measure T cell responses to a tumor-associated antigen and test if T regulatory cells affect those anti-tumor immune responses in patients with colorectal cancer, Invitrogen CD3G antibody (eBioscience, OKT3) was used in blocking or activating experiments on human samples at 0.5 ug/ml. PLoS ONE (2006) ncbi
mouse monoclonal (HIT3a)
  • flow cytometry; human; fig 4
Invitrogen CD3G antibody (eBioscience, HIT3a) was used in flow cytometry on human samples (fig 4). J Virol (2006) ncbi
mouse monoclonal (OKT3)
  • blocking or activating experiments; human
In order to assess the T cell-stimulatory capacity of mature dendritic cells and macrophages using a model of allogeneic MLR, Invitrogen CD3G antibody (eBioscience, OKT-3) was used in blocking or activating experiments on human samples . J Immunol (2006) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human
Invitrogen CD3G antibody (eBioscience, OKT3) was used in flow cytometry on human samples . J Immunol (2006) ncbi
mouse monoclonal (OKT3)
  • flow cytometry; human; fig 1
In order to identify and characterize immature CD2(-/low) T cells in peripheral blood, Invitrogen CD3G antibody (Caltag, OKT3) was used in flow cytometry on human samples (fig 1). J Immunol (2002) ncbi
mouse monoclonal (S4.1 (7D6))
  • immunoprecipitation; human; fig 3
In order to characterize antigens associated with the T3 complex, Invitrogen CD3G antibody (noco, noca) was used in immunoprecipitation on human samples (fig 3). J Biol Chem (1983) ncbi
mouse monoclonal (S4.1)
  • immunoprecipitation; human; fig 3
In order to characterize antigens associated with the T3 complex, Invitrogen CD3G antibody (noco, noca) was used in immunoprecipitation on human samples (fig 3). J Biol Chem (1983) ncbi
mouse monoclonal (S4.1 (7D6))
  • western blot; human
In order to clone the human 20K non-glycosylated T3-epsilon, Invitrogen CD3G antibody (noco, noca) was used in western blot on human samples . Nature (1986) ncbi
mouse monoclonal (S4.1)
  • western blot; human
In order to clone the human 20K non-glycosylated T3-epsilon, Invitrogen CD3G antibody (noco, noca) was used in western blot on human samples . Nature (1986) ncbi
ATCC
mouse monoclonal
  • flow cytometry; human; 1 ug/ml; fig 1
ATCC CD3G antibody (ATCC, CRL-8001) was used in flow cytometry on human samples at 1 ug/ml (fig 1). Oncoimmunology (2016) ncbi
Articles Reviewed
  1. Choi J, Lee E, Kim S, Park S, Oh S, Kang J, et al. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer. BMC Cancer. 2019;19:817 pubmed publisher
  2. Fransen N, Crusius J, Smolders J, Mizee M, Van Eden C, Luchetti S, et al. Post-mortem multiple sclerosis lesion pathology is influenced by single nucleotide polymorphisms. Brain Pathol. 2020;30:106-119 pubmed publisher
  3. Han L, Hu J, Ma B, Wen D, Zhang T, Lu Z, et al. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis. Diagn Pathol. 2019;14:52 pubmed publisher
  4. Escolano A, Gristick H, Abernathy M, Merkenschlager J, Gautam R, Oliveira T, et al. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. Nature. 2019;: pubmed publisher
  5. Zumaquero E, Stone S, Scharer C, Jenks S, Nellore A, Mousseau B, et al. IFNγ induces epigenetic programming of human T-bethi B cells and promotes TLR7/8 and IL-21 induced differentiation. elife. 2019;8: pubmed publisher
  6. Ye Y, Liu M, Tang L, Du F, Liu Y, Hao P, et al. Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis. Arthritis Res Ther. 2019;21:92 pubmed publisher
  7. Collins P, Cella M, Porter S, Li S, Gurewitz G, Hong H, et al. Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells. Cell. 2019;176:348-360.e12 pubmed publisher
  8. Scheper W, Kelderman S, Fanchi L, Linnemann C, Bendle G, de Rooij M, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25:89-94 pubmed publisher
  9. Young M, Mitchell T, Vieira Braga F, Tran M, Stewart B, Ferdinand J, et al. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science. 2018;361:594-599 pubmed publisher
  10. Pulikkan J, Hegde M, Ahmad H, Belaghzal H, Illendula A, Yu J, et al. CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia. Cell. 2018;174:172-186.e21 pubmed publisher
  11. Galperin M, Farenc C, Mukhopadhyay M, Jayasinghe D, Decroos A, Benati D, et al. CD4+ T cell-mediated HLA class II cross-restriction in HIV controllers. Sci Immunol. 2018;3: pubmed publisher
  12. Pizzolla A, Nguyen T, Sant S, Jaffar J, Loudovaris T, Mannering S, et al. Influenza-specific lung-resident memory T cells are proliferative and polyfunctional and maintain diverse TCR profiles. J Clin Invest. 2018;128:721-733 pubmed publisher
  13. Meng Y, Zhou W, Jin L, Liu L, Chang K, Mei J, et al. RANKL-mediated harmonious dialogue between fetus and mother guarantees smooth gestation by inducing decidual M2 macrophage polarization. Cell Death Dis. 2017;8:e3105 pubmed publisher
  14. Chan Y, Zuo J, Inman C, Croft W, Begum J, Croudace J, et al. NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD. Eur J Immunol. 2018;48:316-329 pubmed publisher
  15. Pinaud L, Samassa F, Porat Z, Ferrari M, Belotserkovsky I, Parsot C, et al. Injection of T3SS effectors not resulting in invasion is the main targeting mechanism of Shigella toward human lymphocytes. Proc Natl Acad Sci U S A. 2017;114:9954-9959 pubmed publisher
  16. Kruglova N, Meshkova T, Kopylov A, Mazurov D, Filatov A. Constitutive and activation-dependent phosphorylation of lymphocyte phosphatase-associated phosphoprotein (LPAP). PLoS ONE. 2017;12:e0182468 pubmed publisher
  17. Jiang X, Björkström N, Melum E. Intact CD100-CD72 Interaction Necessary for TCR-Induced T Cell Proliferation. Front Immunol. 2017;8:765 pubmed publisher
  18. Chang A, Dao T, Gejman R, Jarvis C, Scott A, Dubrovsky L, et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest. 2017;127:2705-2718 pubmed publisher
  19. Zheng C, Zheng L, Yoo J, Guo H, Zhang Y, Guo X, et al. Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing. Cell. 2017;169:1342-1356.e16 pubmed publisher
  20. Van Caeneghem Y, De Munter S, Tieppo P, Goetgeluk G, Weening K, Verstichel G, et al. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities. Oncoimmunology. 2017;6:e1283460 pubmed publisher
  21. Khodadoust M, Olsson N, Wagar L, Haabeth O, Chen B, Swaminathan K, et al. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature. 2017;543:723-727 pubmed publisher
  22. Su S, Liao J, Liu J, Huang D, He C, Chen F, et al. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res. 2017;27:461-482 pubmed publisher
  23. Lim A, Li Y, Lopez Lastra S, Stadhouders R, Paul F, Casrouge A, et al. Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. Cell. 2017;168:1086-1100.e10 pubmed publisher
  24. Szabo P, Goswami A, Mazzuca D, Kim K, O Gorman D, Hess D, et al. Rapid and Rigorous IL-17A Production by a Distinct Subpopulation of Effector Memory T Lymphocytes Constitutes a Novel Mechanism of Toxic Shock Syndrome Immunopathology. J Immunol. 2017;198:2805-2818 pubmed publisher
  25. Su S, Zou Z, Chen F, Ding N, Du J, Shao J, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology. 2017;6:e1249558 pubmed publisher
  26. Kim J, Kwon C, Joh J, Sinn D, Choi G, Park J, et al. Differences in Peripheral Blood Lymphocytes between Brand-Name and Generic Tacrolimus Used in Stable Liver Transplant Recipients. Med Princ Pract. 2017;26:221-228 pubmed publisher
  27. Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, et al. Targeting type I interferon-mediated activation restores immune function in chronic HIV infection. J Clin Invest. 2017;127:260-268 pubmed publisher
  28. Ryan P, Sumaria N, Holland C, Bradford C, Izotova N, Grandjean C, et al. Heterogeneous yet stable Vδ2(+) T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc Natl Acad Sci U S A. 2016;113:14378-14383 pubmed
  29. Villanueva Cabello T, Martinez Duncker I. Preparation of CD4+ T Cells for Analysis of GD3 and GD2 Ganglioside Membrane Expression by Microscopy. J Vis Exp. 2016;: pubmed publisher
  30. Tomic A, Varanasi P, Golemac M, Malic S, Riese P, Borst E, et al. Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. PLoS Pathog. 2016;12:e1006015 pubmed publisher
  31. Ribeiro S, Tesio M, Ribot J, Macintyre E, Barata J, Silva Santos B. Casein kinase 2 controls the survival of normal thymic and leukemic ?? T cells via promotion of AKT signaling. Leukemia. 2017;31:1603-1610 pubmed publisher
  32. Cuff A, Robertson F, Stegmann K, Pallett L, Maini M, Davidson B, et al. Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. J Immunol. 2016;197:4283-4291 pubmed
  33. Keefer M, Zheng B, Rosenberg A, Kobie J. Increased Steady-State Memory B Cell Subsets Among High-Risk Participants in an HIV Vaccine Trial. AIDS Res Hum Retroviruses. 2016;32:1143-1148 pubmed
  34. Guillou L, Babataheri A, Saitakis M, Bohineust A, Dogniaux S, Hivroz C, et al. T-lymphocyte passive deformation is controlled by unfolding of membrane surface reservoirs. Mol Biol Cell. 2016;27:3574-3582 pubmed
  35. Pageon S, Nicovich P, Mollazade M, Tabarin T, Gaus K. Clus-DoC: a combined cluster detection and colocalization analysis for single-molecule localization microscopy data. Mol Biol Cell. 2016;27:3627-3636 pubmed
  36. Pageon S, Tabarin T, Yamamoto Y, Ma Y, Nicovich P, Bridgeman J, et al. Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination. Proc Natl Acad Sci U S A. 2016;113:E5454-63 pubmed publisher
  37. Xing Y, Cao R, Hu H. TLR and NLRP3 inflammasome-dependent innate immune responses to tumor-derived autophagosomes (DRibbles). Cell Death Dis. 2016;7:e2322 pubmed publisher
  38. Sullivan K, Lewis H, Hill A, Pandey A, Jackson L, Cabral J, et al. Trisomy 21 consistently activates the interferon response. elife. 2016;5: pubmed publisher
  39. Sadallah S, Schmied L, Eken C, Charoudeh H, Amicarella F, Schifferli J. Platelet-Derived Ectosomes Reduce NK Cell Function. J Immunol. 2016;197:1663-71 pubmed publisher
  40. Kang J, Park S, Jeong S, Han M, Lee C, Lee K, et al. Epigenetic regulation of Kcna3-encoding Kv1.3 potassium channel by cereblon contributes to regulation of CD4+ T-cell activation. Proc Natl Acad Sci U S A. 2016;113:8771-6 pubmed publisher
  41. Piepenbrink M, Samuel M, Zheng B, Carter B, Fucile C, Bunce C, et al. Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users. PLoS ONE. 2016;11:e0158641 pubmed publisher
  42. Mo A, Jackson S, Varma K, Carpino A, Giardina C, Devers T, et al. Distinct Transcriptional Changes and Epithelial-Stromal Interactions Are Altered in Early-Stage Colon Cancer Development. Mol Cancer Res. 2016;14:795-804 pubmed publisher
  43. Hahn S, Neuhoff A, Landsberg J, Schupp J, Eberts D, Leukel P, et al. A key role of GARP in the immune suppressive tumor microenvironment. Oncotarget. 2016;7:42996-43009 pubmed publisher
  44. Yin W, Tong S, Zhang Q, Shao J, Liu Q, Peng H, et al. Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Sci Rep. 2016;6:26296 pubmed publisher
  45. Kay A, Strauss Albee D, Blish C. Application of Mass Cytometry (CyTOF) for Functional and Phenotypic Analysis of Natural Killer Cells. Methods Mol Biol. 2016;1441:13-26 pubmed publisher
  46. Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P. Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer. 2016;4:21 pubmed publisher
  47. Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, et al. PD-1 expression conditions T cell avidity within an antigen-specific repertoire. Oncoimmunology. 2016;5:e1104448 pubmed
  48. Gao J, Duan Z, Zhang L, Huang X, Long L, Tu J, et al. Failure recovery of circulating NKG2D+CD56dimNK cells in HBV-associated hepatocellular carcinoma after hepatectomy predicts early recurrence. Oncoimmunology. 2016;5:e1048061 pubmed
  49. Hu H, Wang H, Xiao Y, Jin J, Chang J, Zou Q, et al. Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination. J Exp Med. 2016;213:399-414 pubmed publisher
  50. Su S, Hu B, Shao J, Shen B, Du J, Du Y, et al. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 2016;6:20070 pubmed publisher
  51. Gonzalez S, Taborda N, Correa L, Castro G, Hernandez J, Montoya C, et al. Particular activation phenotype of T cells expressing HLA-DR but not CD38 in GALT from HIV-controllers is associated with immune regulation and delayed progression to AIDS. Immunol Res. 2016;64:765-74 pubmed publisher
  52. Vivar O, Masi G, Carpier J, Magalhaes J, Galgano D, Pazour G, et al. IFT20 controls LAT recruitment to the immune synapse and T-cell activation in vivo. Proc Natl Acad Sci U S A. 2016;113:386-91 pubmed publisher
  53. Westman J, Papareddy P, Dahlgren M, Chakrakodi B, Norrby Teglund A, Smeds E, et al. Extracellular Histones Induce Chemokine Production in Whole Blood Ex Vivo and Leukocyte Recruitment In Vivo. PLoS Pathog. 2015;11:e1005319 pubmed publisher
  54. Kobayashi S, Watanabe T, Suzuki R, Furu M, Ito H, Ito J, et al. TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. Eur J Immunol. 2016;46:360-71 pubmed publisher
  55. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed publisher
  56. Venkatasubramanian S, Tripathi D, Tucker T, Paidipally P, Cheekatla S, Welch E, et al. Tissue factor expression by myeloid cells contributes to protective immune response against Mycobacterium tuberculosis infection. Eur J Immunol. 2016;46:464-79 pubmed publisher
  57. Spiesberger K, Paulfranz F, Egger A, Reiser J, Vogl C, Rudolf Scholik J, et al. Large-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle. PLoS ONE. 2015;10:e0140471 pubmed publisher
  58. Schulz A, Mälzer J, Domingo C, Jürchott K, Grützkau A, Babel N, et al. Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans. J Immunol. 2015;195:4699-711 pubmed publisher
  59. Okoye Okafor U, Bartholdy B, Cartier J, Gao E, Pietrak B, Rendina A, et al. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol. 2015;11:878-86 pubmed publisher
  60. Mitson Salazar A, Yin Y, Wansley D, Young M, Bolan H, Arceo S, et al. Hematopoietic prostaglandin D synthase defines a proeosinophilic pathogenic effector human T(H)2 cell subpopulation with enhanced function. J Allergy Clin Immunol. 2016;137:907-18.e9 pubmed publisher
  61. Silacci M, Lembke W, Woods R, Attinger Toller I, Baenziger Tobler N, Batey S, et al. Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases. MAbs. 2016;8:141-9 pubmed publisher
  62. Broos C, van Nimwegen M, Kleinjan A, Ten Berge B, Muskens F, In t Veen J, et al. Impaired survival of regulatory T cells in pulmonary sarcoidosis. Respir Res. 2015;16:108 pubmed publisher
  63. Nakatsukasa H, Zhang D, Maruyama T, Chen H, Cui K, Ishikawa M, et al. The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells. Nat Immunol. 2015;16:1077-84 pubmed publisher
  64. Japp A, Kursunel M, Meier S, Mälzer J, Li X, Rahman N, et al. Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression. Cancer Immunol Immunother. 2015;64:1487-94 pubmed publisher
  65. Klammt C, Novotná L, Li D, Wolf M, Blount A, Zhang K, et al. T cell receptor dwell times control the kinase activity of Zap70. Nat Immunol. 2015;16:961-9 pubmed publisher
  66. Weist B, Wehler P, El Ahmad L, Schmueck Henneresse M, Millward J, Nienen M, et al. A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients. Kidney Int. 2015;88:1293-1303 pubmed publisher
  67. Owens G, Erickson K, Malone C, Pan C, Huynh M, Chang J, et al. Evidence for the involvement of gamma delta T cells in the immune response in Rasmussen encephalitis. J Neuroinflammation. 2015;12:134 pubmed publisher
  68. Wang Y, Zhong H, Xie X, Chen C, Huang D, Shen L, et al. Long noncoding RNA derived from CD244 signaling epigenetically controls CD8+ T-cell immune responses in tuberculosis infection. Proc Natl Acad Sci U S A. 2015;112:E3883-92 pubmed publisher
  69. Mende N, Kuchen E, Lesche M, Grinenko T, Kokkaliaris K, Hanenberg H, et al. CCND1-CDK4-mediated cell cycle progression provides a competitive advantage for human hematopoietic stem cells in vivo. J Exp Med. 2015;212:1171-83 pubmed publisher
  70. Fahlbusch F, Ruebner M, Huebner H, Volkert G, Bartunik H, Winterfeld I, et al. Trophoblast expression dynamics of the tumor suppressor gene gastrokine 2. Histochem Cell Biol. 2015;144:281-91 pubmed publisher
  71. Kim S, Theunissen J, Balibalos J, Liao Chan S, Babcock M, Wong T, et al. A novel antibody-drug conjugate targeting SAIL for the treatment of hematologic malignancies. Blood Cancer J. 2015;5:e316 pubmed publisher
  72. Tsai P, Chang Y, Lee Y, Ko Y, Yang Y, Lin C, et al. Differentiation of blood T cells: Reprogramming human induced pluripotent stem cells into neuronal cells. J Chin Med Assoc. 2015;78:353-9 pubmed publisher
  73. Schmueck Henneresse M, Sharaf R, Vogt K, Weist B, Landwehr Kenzel S, Fuehrer H, et al. Peripheral blood-derived virus-specific memory stem T cells mature to functional effector memory subsets with self-renewal potency. J Immunol. 2015;194:5559-67 pubmed publisher
  74. Anandasabapathy N, Breton G, Hurley A, Caskey M, Trumpfheller C, Sarma P, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015;50:924-30 pubmed publisher
  75. Vassena L, Giuliani E, Koppensteiner H, Bolduan S, Schindler M, Doria M. HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes. J Virol. 2015;89:5687-700 pubmed publisher
  76. Dudek Perić A, Ferreira G, Muchowicz A, Wouters J, Prada N, Martin S, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015;75:1603-14 pubmed publisher
  77. Tsai C, Liong K, Gunalan M, Li N, Lim D, Fisher D, et al. Type I IFNs and IL-18 regulate the antiviral response of primary human γδ T cells against dendritic cells infected with Dengue virus. J Immunol. 2015;194:3890-900 pubmed publisher
  78. Claiborne D, Prince J, Scully E, Macharia G, Micci L, Lawson B, et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci U S A. 2015;112:E1480-9 pubmed publisher
  79. Severson J, Serracino H, Mateescu V, Raeburn C, McIntyre R, Sams S, et al. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015;3:620-30 pubmed publisher
  80. Comrie W, Babich A, Burkhardt J. F-actin flow drives affinity maturation and spatial organization of LFA-1 at the immunological synapse. J Cell Biol. 2015;208:475-91 pubmed publisher
  81. Chauhan A, Chen C, Moore T, DiPaolo R. Induced expression of FcγRIIIa (CD16a) on CD4+ T cells triggers generation of IFN-γhigh subset. J Biol Chem. 2015;290:5127-40 pubmed publisher
  82. Ito S, Barrett A, Dutra A, Pak E, Miner S, Keyvanfar K, et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res. 2015;14:95-104 pubmed publisher
  83. Caramalho I, Nunes Silva V, Pires A, Mota C, Pinto A, Nunes Cabaço H, et al. Human regulatory T-cell development is dictated by Interleukin-2 and -15 expressed in a non-overlapping pattern in the thymus. J Autoimmun. 2015;56:98-110 pubmed publisher
  84. Van Eyck L, Hershfield M, Pombal D, Kelly S, Ganson N, Moens L, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015;135:283-7.e5 pubmed publisher
  85. Chovancová J, Bernard T, Stehlíková O, Sálek D, Janíková A, Mayer J, et al. Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel 8-Color Flow Cytometry Approach. Cytometry B Clin Cytom. 2014;: pubmed publisher
  86. Willmann K, Klaver S, DoÄŸu F, Santos Valente E, Garncarz W, Bilic I, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun. 2014;5:5360 pubmed publisher
  87. Freeman A, Bridge J, Maruthayanar P, Overgaard N, Jung J, Simpson F, et al. Comparative immune phenotypic analysis of cutaneous Squamous Cell Carcinoma and Intraepidermal Carcinoma in immune-competent individuals: proportional representation of CD8+ T-cells but not FoxP3+ Regulatory T-cells is associated with disease stage. PLoS ONE. 2014;9:e110928 pubmed publisher
  88. Lim D, Yawata N, Selva K, Li N, Tsai C, Yeong L, et al. The combination of type I IFN, TNF-α, and cell surface receptor engagement with dendritic cells enables NK cells to overcome immune evasion by dengue virus. J Immunol. 2014;193:5065-75 pubmed publisher
  89. Gerna G, Lilleri D, Fornara C, Bruno F, Gabanti E, Cane I, et al. Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host. J Gen Virol. 2015;96:360-9 pubmed publisher
  90. O Regan N, Steinfelder S, Venugopal G, Rao G, Lucius R, Srikantam A, et al. Brugia malayi microfilariae induce a regulatory monocyte/macrophage phenotype that suppresses innate and adaptive immune responses. PLoS Negl Trop Dis. 2014;8:e3206 pubmed publisher
  91. Cucak H, Vistisen D, Witte D, Philipsen A, Rosendahl A. Reduction of specific circulating lymphocyte populations with metabolic risk factors in patients at risk to develop type 2 diabetes. PLoS ONE. 2014;9:e107140 pubmed publisher
  92. Abramowski P, Ogrodowczyk C, Martin R, Pongs O. A truncation variant of the cation channel P2RX5 is upregulated during T cell activation. PLoS ONE. 2014;9:e104692 pubmed publisher
  93. Ramirez L, Arango T, Thompson E, Naji M, Tebas P, Boyer J. High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART. J Leukoc Biol. 2014;96:1055-63 pubmed publisher
  94. Kreiser S, Eckhardt J, Kuhnt C, Stein M, Krzyzak L, Seitz C, et al. Murine CD83-positive T cells mediate suppressor functions in vitro and in vivo. Immunobiology. 2015;220:270-9 pubmed publisher
  95. Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, et al. Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody. Clin Cancer Res. 2014;20:5052-63 pubmed publisher
  96. Weist B, Schmueck M, Fuehrer H, Sattler A, Reinke P, Babel N. The role of CD4(+) T cells in BKV-specific T cell immunity. Med Microbiol Immunol. 2014;203:395-408 pubmed publisher
  97. Longman R, Diehl G, Victorio D, Huh J, Galan C, Miraldi E, et al. CX?CR1? mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J Exp Med. 2014;211:1571-83 pubmed publisher
  98. Butcher L, Garcia M, Arnold M, Ueno H, Goel A, Boland C. Immune response to JC virus T antigen in patients with and without colorectal neoplasia. Gut Microbes. 2014;5:468-75 pubmed publisher
  99. Wilson E, Singh A, Hullsiek K, Gibson D, Henry W, Lichtenstein K, et al. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis. 2014;210:1396-406 pubmed publisher
  100. Barbosa R, Silva S, Silva S, Melo A, Pereira Santos M, Barata J, et al. Reduced BAFF-R and increased TACI expression in common variable immunodeficiency. J Clin Immunol. 2014;34:573-83 pubmed publisher
  101. Tarbox J, Keppel M, Topcagic N, Mackin C, Ben Abdallah M, Baszis K, et al. Elevated double negative T cells in pediatric autoimmunity. J Clin Immunol. 2014;34:594-9 pubmed publisher
  102. Mao C, Mou X, Zhou Y, Yuan G, Xu C, Liu H, et al. Tumor-activated TCR??? T cells from gastric cancer patients induce the antitumor immune response of TCR??? T cells via their antigen-presenting cell-like effects. J Immunol Res. 2014;2014:593562 pubmed publisher
  103. Ye W, Xing Y, Paustian C, van de Ven R, Moudgil T, Hilton T, et al. Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells. J Transl Med. 2014;12:100 pubmed publisher
  104. Cartellieri M, Koristka S, Arndt C, Feldmann A, Stamova S, von Bonin M, et al. A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS ONE. 2014;9:e93745 pubmed publisher
  105. Abramowski P, Otto B, Martin R. The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response. PLoS ONE. 2014;9:e91970 pubmed publisher
  106. Le Saout C, Hasley R, Imamichi H, Tcheung L, Hu Z, Luckey M, et al. Chronic exposure to type-I IFN under lymphopenic conditions alters CD4 T cell homeostasis. PLoS Pathog. 2014;10:e1003976 pubmed publisher
  107. Magri G, Miyajima M, Bascones S, Mortha A, Puga I, Cassis L, et al. Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat Immunol. 2014;15:354-364 pubmed publisher
  108. Lyngaa R, Pedersen N, Schrama D, Thrue C, Ibrani D, Met O, et al. T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res. 2014;20:1768-78 pubmed publisher
  109. Sereti I, Estes J, Thompson W, Morcock D, Fischl M, Croughs T, et al. Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration. PLoS Pathog. 2014;10:e1003890 pubmed publisher
  110. Chang S, Kohrt H, Maecker H. Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother. 2014;63:713-9 pubmed publisher
  111. Yang C, Li J, Chiu L, Lan J, Chen D, Chuang H, et al. Dual-specificity phosphatase 14 (DUSP14/MKP6) negatively regulates TCR signaling by inhibiting TAB1 activation. J Immunol. 2014;192:1547-57 pubmed publisher
  112. Rodriguez M, Loyd C, Ding X, Karim A, MCDONALD D, Canaday D, et al. Mycobacterial phosphatidylinositol mannoside 6 (PIM6) up-regulates TCR-triggered HIV-1 replication in CD4+ T cells. PLoS ONE. 2013;8:e80938 pubmed publisher
  113. Rapetti L, Chavele K, Evans C, Ehrenstein M. B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis. Ann Rheum Dis. 2015;74:294-302 pubmed publisher
  114. Zouk H, d Hennezel E, Du X, Ounissi Benkalha H, Piccirillo C, Polychronakos C. Functional evaluation of the role of C-type lectin domain family 16A at the chromosome 16p13 locus. Clin Exp Immunol. 2014;175:485-97 pubmed publisher
  115. Krishnan S, Wilson E, Sheikh V, Rupert A, Mendoza D, Yang J, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis. 2014;209:931-9 pubmed publisher
  116. Didigu C, Wilen C, Wang J, Duong J, Secreto A, Danet Desnoyers G, et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood. 2014;123:61-9 pubmed publisher
  117. Tan A, Hoang L, Chin D, Rasmussen E, Lopatin U, Hart S, et al. Reduction of HBV replication prolongs the early immunological response to IFN? therapy. J Hepatol. 2014;60:54-61 pubmed publisher
  118. Melis L, Van Praet L, Pircher H, Venken K, Elewaut D. Senescence marker killer cell lectin-like receptor G1 (KLRG1) contributes to TNF-? production by interaction with its soluble E-cadherin ligand in chronically inflamed joints. Ann Rheum Dis. 2014;73:1223-31 pubmed publisher
  119. Introini A, Vanpouille C, Lisco A, Grivel J, Margolis L. Interleukin-7 facilitates HIV-1 transmission to cervico-vaginal tissue ex vivo. PLoS Pathog. 2013;9:e1003148 pubmed publisher
  120. Frahm M, Picking R, Kuruc J, McGee K, Gay C, Eron J, et al. CD4+CD8+ T cells represent a significant portion of the anti-HIV T cell response to acute HIV infection. J Immunol. 2012;188:4289-96 pubmed publisher
  121. Meeths M, Chiang S, Wood S, Entesarian M, Schlums H, Bang B, et al. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood. 2011;118:5783-93 pubmed publisher
  122. Magrini E, Szabo I, Doni A, Cibella J, Viola A. Serotonin-mediated tuning of human helper T cell responsiveness to the chemokine CXCL12. PLoS ONE. 2011;6:e22482 pubmed publisher
  123. Ruffell B, Au A, Rugo H, Esserman L, Hwang E, Coussens L. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109:2796-801 pubmed publisher
  124. Correia M, Costa A, Uhrberg M, Cardoso E, Arosa F. IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology. 2011;216:604-12 pubmed publisher
  125. Markley J, Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood. 2010;115:3508-19 pubmed publisher
  126. Oo Y, Weston C, Lalor P, Curbishley S, Withers D, Reynolds G, et al. Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol. 2010;184:2886-98 pubmed publisher
  127. Kapoor V, Hakim F, Rehman N, Gress R, Telford W. Quantum dots thermal stability improves simultaneous phenotype-specific telomere length measurement by FISH-flow cytometry. J Immunol Methods. 2009;344:6-14 pubmed publisher
  128. Karagoz B, Bilgi O, Gumus M, Erikci A, Sayan O, Turken O, et al. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol. 2010;27:29-33 pubmed publisher
  129. Richardson M, Carroll R, Stremlau M, Korokhov N, Humeau L, Silvestri G, et al. Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol. 2008;82:11117-28 pubmed publisher
  130. Kueng H, Leb V, Haiderer D, Raposo G, Thery C, Derdak S, et al. General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol. 2007;81:8666-76 pubmed
  131. Clarke S, Betts G, Plant A, Wright K, El Shanawany T, Harrop R, et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE. 2006;1:e129 pubmed
  132. Xin K, Mizukami H, Urabe M, Toda Y, Shinoda K, Yoshida A, et al. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J Virol. 2006;80:11899-910 pubmed
  133. Hoves S, Krause S, Schutz C, Halbritter D, Scholmerich J, Herfarth H, et al. Monocyte-derived human macrophages mediate anergy in allogeneic T cells and induce regulatory T cells. J Immunol. 2006;177:2691-8 pubmed
  134. Quiroga M, Pasquinelli V, Martinez G, Jurado J, Zorrilla L, Musella R, et al. Inducible costimulator: a modulator of IFN-gamma production in human tuberculosis. J Immunol. 2006;176:5965-74 pubmed
  135. Loza M, Perussia B. Peripheral immature CD2-/low T cell development from type 2 to type 1 cytokine production. J Immunol. 2002;169:3061-8 pubmed
  136. Borst J, Alexander S, Elder J, Terhorst C. The T3 complex on human T lymphocytes involves four structurally distinct glycoproteins. J Biol Chem. 1983;258:5135-41 pubmed
  137. Gold D, Puck J, Pettey C, Cho M, Coligan J, Woody J, et al. Isolation of cDNA clones encoding the 20K non-glycosylated polypeptide chain of the human T-cell receptor/T3 complex. Nature. 1986;321:431-4 pubmed